Drug Discovery · Disease Dynamics
We model disease as a dynamic system — and explore when interventions can shift its state.
DISCUSS THE APPROACHMolentio encodes disease as a system of interacting biological processes, connected through their causal structure:
Disease progression is not linear — it is state-dependent.
Disease systems exhibit multiple stable states. Between them lies a boundary — the point beyond which a given intervention is insufficient to return the system to a healthy state.
We aim to determine whether a system state can be shifted across this boundary, and the conditions required to do so.
Two stable disease states separated by a potential barrier. The teal basin is the healthy attractor; the amber basin is the fibrotic attractor. The patient marker sits within the fibrotic basin, but close enough to the boundary that a well-targeted intervention may still shift the system back to the healthy state.
Therapy succeeds only if the system can still be shifted.
Molentio translates mechanistic disease models into actionable insights for drug development.
Identify which disease states are theoretically reversible under a given intervention.
Determine whether a target has sufficient leverage to shift system dynamics.
Identify compensatory pathways and required multi-target interventions.
Align intervention mechanism with disease state to improve signal detection.
Clinical measurements provide a partial view of disease. Molentio focuses on estimating the underlying mechanistic state that drives progression.
By combining observed data with model constraints, we determine where a patient's system lies — and which interventions remain viable.
What matters is not what we observe — but the state the system is in.
Our initial work focuses on chronic kidney disease, where fibrosis progression exhibits clear dynamical structure — making it an ideal validation ground for causal dynamical modeling.
This serves as the foundation for expansion into broader fibrotic diseases.
We engage with biotech and pharma teams to explore how causal dynamical models can be applied to drug discovery and development.
Each collaboration aims to generate program-specific, mechanistically grounded insights for therapeutic development.
Explore collaboration